Our study shows that targeting truncated tau at Asp421 with monoclonal antibody 5G2 prevents tau-mediated toxicity and leads to clearance of pathological tau both in primary tauopathy neurons and in a tauopathy mixed cortical culture. The gene discussed is MAPT; the disease is tauopathy.